Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer
Received 29 January 2018
Accepted for publication 7 May 2018
Published 16 July 2018 Volume 2018:10 Pages 2031—2046
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Antonella D'Anneo
Shi Jin,1,* Shoubo Cao,1,2,* Aleksei Grigorev,3,* Jianhua Li,4 Qingwei Meng,1 Chunyan Wang,1,2 Meiyan Feng,5 Jing Hu,1 Feng Jiang,3 Yan Yu1
1Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China; 2Department of Medical Oncology, Linyi People’s Hospital, Linyi City, People’s Republic of China; 3School of Computer Science and Technology, Harbin Institute of Technology, Harbin, People’s Republic of China; 4Department of Neurosurgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China; 5Department of Pathology, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China
*These authors contributed equally to this work
Background: Cancer/testis antigen (CTA) expression was found to be highly heterogeneous in previous studies. We aimed to establish a precision CTA profiling in resected stage III non-small cell lung cancer (NSCLC) and demonstrate the best CTA combination covering the widest range of NSCLC cases.
Materials and methods: The expression of 10 CTAs was evaluated in 200 resected stage III NSCLC tissue specimens at protein level. Hierarchical clustering and python programming language analyses was used to demonstrate CTA expression and coverage.
Results: The most commonly expressed CTAs for total cases were MAGEA1 (60.0%), MAGEA10 (50.0%), and KK-LC-1 (47.5%). CTA expression was histology dependent, and concurrent expression was common. The best 2, 3, and 4 CTA combination covered 72.0%, 76.5%, and 79.5% of total cases, respectively. Stratified analysis based on variable clinicopathological characteristics achieved the maximum coverage of 92.3% with only 2 CTA combination in patients with features of male sex, positive smoking history, and adenocarcinoma, compared with a 85.0% coverage when 10 CTAs were assessed. Selected CTA expression was correlated with prognosis based on subgroup analysis. No significant difference was found between CTA expression and epidermal growth factor receptor mutant status.
Conclusion: We established an individualized CTA profiling in resected stage III NSCLC based on 10 CTA expression. With the help of computer programming language, the goal of the maximum CTA expression coverage was reached by using the least CTA combination based on sex, smoking history, and histology. These results were significant for the further study of CTA-specific T-cell immunotherapy.
Keywords: lung cancer, cancer/testis antigens, immunotherapy, prognosis, profiling
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]